{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:02:19Z","timestamp":1786114939804,"version":"build-2736575974"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020201","name":"Indian Institute of Technology Palakkad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020201","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"India Ministry of Science & Technology Department of Biotechnology","doi-asserted-by":"publisher","award":["BT\/RLF\/Re-entry\/75\/2020"],"award-info":[{"award-number":["BT\/RLF\/Re-entry\/75\/2020"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.biopha.2026.119706","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:09:15Z","timestamp":1783498155000},"page":"119706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Unleashing the prospects of nanomaterials in the treatment of autoimmune and inflammatory diseases"],"prefix":"10.1016","volume":"201","author":[{"given":"Vijayakumar G.","family":"Gayathri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Abdul","family":"Rasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0498-9808","authenticated-orcid":false,"given":"Jagadeesh","family":"Bayry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119706_bib1","series-title":"The Autoimmune Diseases (Sixth Edition)","first-page":"45","article-title":"Chapter 4 - Innate and Adaptive Systems of Immunity","author":"Delves","year":"2020"},{"key":"10.1016\/j.biopha.2026.119706_bib2","series-title":"Cellular and Molecular Immunology E-Book: Cellular and Molecular Immunology E-Book","author":"Abbas","year":"2014"},{"issue":"2","key":"10.1016\/j.biopha.2026.119706_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13223-018-0278-1","article-title":"An introduction to immunology and immunopathology","volume":"14","author":"Marshall","year":"2018","journal-title":"Allergy Asthma Clin. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119706_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s12016-015-8493-8","article-title":"Environmental Basis of Autoimmunity","volume":"50","author":"Floreani","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119706_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J. Intern. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119706_bib6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","article-title":"Pathogenesis of autoimmune disease","volume":"19","author":"Pisetsky","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119706_bib7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJM200108023450506","article-title":"Autoimmune Diseases","volume":"345","author":"Davidson","year":"2001","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119706_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2022.102266","article-title":"The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention","volume":"80","author":"Miller","year":"2023","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.autrev.2010.08.016","article-title":"Systemic lupus erythematosus: Clinical presentations","volume":"10","author":"Smith","year":"2010","journal-title":"Autoimmun. Rev."},{"issue":"16","key":"10.1016\/j.biopha.2026.119706_bib10","doi-asserted-by":"crossref","first-page":"5714","DOI":"10.3390\/jcm14165714","article-title":"Autoantibodies in Systemic Lupus Erythematosus: Diagnostic and Pathogenic Insights","volume":"14","author":"Pagkopoulou","year":"2025","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.biopha.2026.119706_bib11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/art.41417","article-title":"Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention: An Emerging Paradigm Shift","volume":"73","author":"Deane","year":"2021","journal-title":"Arthritis & Rheumatol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119706_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/BOR.0000000000001006","article-title":"Autoantibodies in rheumatoid arthritis \u2013 rheumatoid factor, anticitrullinated protein antibodies and beyond","volume":"36","author":"Steiner","year":"2024","journal-title":"Curr. Opin. Rheumatol."},{"issue":"19","key":"10.1016\/j.biopha.2026.119706_bib13","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"New. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2026.119706_bib14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12016-022-08946-w","article-title":"Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers","volume":"64","author":"Cavazzana","year":"2023","journal-title":"Clin. Rev. Allergy & Immunol."},{"issue":"16","key":"10.1016\/j.biopha.2026.119706_bib15","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 Disease","volume":"375","author":"Smith","year":"2016","journal-title":"New. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib16","article-title":"Type 1 diabetes mellitus","volume":"3","author":"Katsarou","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"6","key":"10.1016\/j.biopha.2026.119706_bib17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41577-023-00985-4","article-title":"The immunology of type 1 diabetes","volume":"24","author":"Herold","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2026.119706_bib18","series-title":"Multiple Sclerosis","first-page":"1","article-title":"Chapter 1 - Clinical Manifestations of Multiple Sclerosis: An Overview","author":"Javalkar","year":"2016"},{"issue":"12","key":"10.1016\/j.biopha.2026.119706_bib19","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41577-022-00718-z","article-title":"The immunology of multiple sclerosis","volume":"22","author":"Attfield","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119706_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12016-021-08868-z","article-title":"Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo","volume":"61","author":"Wang","year":"2021","journal-title":"Clin. Rev. Allergy & Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119706_bib21","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40618-019-01079-6","article-title":"Epidemiology, pathogenesis, and diagnosis of Addison\u2019s disease in adults","volume":"42","author":"Betterle","year":"2019","journal-title":"J. Endocrinol. Investig."},{"issue":"2","key":"10.1016\/j.biopha.2026.119706_bib22","first-page":"171","article-title":"Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update","volume":"131","author":"Prieto-Pe\u00f1a","year":"2021","journal-title":"Pol. Arch. Intern. Med."},{"issue":"125","key":"10.1016\/j.biopha.2026.119706_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003504","article-title":"Treating Human Autoimmunity: Current Practice and Future Prospects","volume":"4","author":"Rosenblum","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.biopha.2026.119706_bib24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK\u2013STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2026.119706_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106023","article-title":"Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports","volume":"56","author":"Gaspari","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"8","key":"10.1016\/j.biopha.2026.119706_bib27","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s12325-013-0047-y","article-title":"Tofacitinib for Treatment of Rheumatoid Arthritis","volume":"30","author":"Rakieh","year":"2013","journal-title":"Adv. Ther."},{"key":"10.1016\/j.biopha.2026.119706_bib28","series-title":"Prednisone","article-title":"Treasure Island (FL)","author":"Puckett","year":"2026"},{"key":"10.1016\/j.biopha.2026.119706_bib29","first-page":"349","article-title":"Corticosteroids","volume":"27","author":"Vardanyan","year":"2006"},{"key":"10.1016\/j.biopha.2026.119706_bib30","series-title":"Dexamethasone","author":"Johnson","year":"2026"},{"issue":"5","key":"10.1016\/j.biopha.2026.119706_bib31","doi-asserted-by":"crossref","first-page":"691","DOI":"10.25259\/IJDVL_1152_2022","article-title":"JAK-STAT inhibitors in Immune mediated diseases: An Overview","volume":"89","author":"Shah","year":"2023","journal-title":"Indian. J. Dermatol. Venereol. Leprol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119706_bib33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/13543784.2020.1733527","article-title":"The use of biologics in the treatment of autoimmune liver disease","volume":"29","author":"Chang","year":"2020","journal-title":"Expert. Opin. Investig. Drugs"},{"issue":"12","key":"10.1016\/j.biopha.2026.119706_bib34","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.biopha.2026.119706_bib35","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1741-7015-11-88","article-title":"Biologic therapy for autoimmune diseases: an update","volume":"11","author":"Rosman","year":"2013","journal-title":"BMC Med."},{"issue":"10","key":"10.1016\/j.biopha.2026.119706_bib36","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrrheum.2009.181","article-title":"Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis","volume":"5","author":"Taylor","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.biopha.2026.119706_bib37","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.coph.2018.05.010","article-title":"Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases","volume":"41","author":"Hafeez","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaci.2015.10.023","article-title":"Alterations in immune function with biologic therapies for autoimmune disease","volume":"137","author":"Her","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119706_bib39","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jaip.2023.04.002","article-title":"Intravenous Immunoglobulin: Mechanism of Action in Autoimmune and Inflammatory Conditions","volume":"11","author":"Bayry","year":"2023","journal-title":"Journal Allergy Clinical Immunology Practice"},{"issue":"2","key":"10.1016\/j.biopha.2026.119706_bib40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1021\/ab500084g","article-title":"Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies","volume":"1","author":"Ediriwickrema","year":"2015","journal-title":"ACS Biomater. Sci. & Eng."},{"issue":"null","key":"10.1016\/j.biopha.2026.119706_bib41","first-page":"1005","article-title":"Nanotherapeutics in the EU: an overview on current state and future directions","volume":"9","author":"Hafner","year":"2014","journal-title":"Int. J. Nanomed."},{"issue":"8","key":"10.1016\/j.biopha.2026.119706_bib42","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/cvr\/cvae099","article-title":"Targeting macrophages with multifunctional nanoparticles to detect and prevent atherosclerotic cardiovascular disease","volume":"120","author":"Nankivell","year":"2024","journal-title":"Cardiovasc. Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119706_bib43","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.nano.2014.12.003","article-title":"Therapeutic applications of nanomedicine in autoimmune diseases: From immunosuppression to tolerance induction","volume":"11","author":"Gharagozloo","year":"2015","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"20","key":"10.1016\/j.biopha.2026.119706_bib44","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.3390\/molecules24203744","article-title":"Biodegradable polymers for gene delivery","volume":"24","author":"Thomas","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119706_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1267091","article-title":"The role of inflammation in autoimmune disease: a therapeutic target","volume":"14","author":"Xiang","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-021-01096-0","article-title":"Nanomaterials for cancer therapy: current progress and perspectives","volume":"14","author":"Cheng","year":"2021","journal-title":"J. Hematol. & Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119706_bib47","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1039\/c2cs15327k","article-title":"Design of polymeric nanoparticles for biomedical delivery applications","volume":"41","author":"Elsabahy","year":"2012","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib48","doi-asserted-by":"crossref","DOI":"10.26599\/POM.2024.9140082","article-title":"Advanced application of metal nanoparticles in the diagnosis and treatment of rheumatoid arthritis","volume":"4","author":"Zhang","year":"2025","journal-title":"Polyoxometalates"},{"issue":"11","key":"10.1016\/j.biopha.2026.119706_bib49","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1007\/s10787-025-01982-w","article-title":"Innovative polymer-based therapeutics targeting inflammation for responsive drug delivery in disease treatment","volume":"33","author":"Lipsi","year":"2025","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.biopha.2026.119706_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116493","article-title":"Carbon nanomaterials as emerging nanotherapeutic platforms to tackle the rising tide of cancer \u2013 A review","volume":"51","author":"Bagheri","year":"2021","journal-title":"Bioorg. & Med. Chem."},{"issue":"9","key":"10.1016\/j.biopha.2026.119706_bib51","article-title":"Carbon Nanomaterials Applied for the Treatment of Inflammatory Diseases: Preclinical Evidence","volume":"3","author":"Soltani","year":"2020","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2026.119706_bib52","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/joim.12280","article-title":"Emerging concepts in dendrimer-based nanomedicine: from design principles to clinical applications","volume":"276","author":"Kannan","year":"2014","journal-title":"J. Intern. Med."},{"issue":"7","key":"10.1016\/j.biopha.2026.119706_bib53","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41565-021-00931-2","article-title":"Extracellular vesicles as a next-generation drug delivery platform","volume":"16","author":"Herrmann","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biopha.2026.119706_bib54","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jconrel.2023.11.006","article-title":"Extracellular vesicles encapsulated with caspase-1 inhibitor ameliorate experimental autoimmune myasthenia gravis through targeting macrophages","volume":"364","author":"Zhou","year":"2023","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib55","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s12668-022-00941-x","article-title":"A Comprehensive Review on Novel Liposomal Methodologies, Commercial Formulations, Clinical Trials and Patents","volume":"12","author":"Andra","year":"2022","journal-title":"BioNanoScience"},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib56","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1186\/s12951-022-01746-6","article-title":"Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment","volume":"20","author":"Wu","year":"2022","journal-title":"J. Nanobiotechnology"},{"issue":"17","key":"10.1016\/j.biopha.2026.119706_bib57","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1039\/D2NA00229A","article-title":"Recent advances in nanoparticle-based drug delivery systems for rheumatoid arthritis treatment","volume":"4","author":"Nasra","year":"2022","journal-title":"Nanoscale Adv."},{"issue":"10","key":"10.1016\/j.biopha.2026.119706_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103648","article-title":"Immunopathogenesis of systemic lupus erythematosus: An update","volume":"23","author":"Arnaud","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.biopha.2026.119706_bib59","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.biomaterials.2019.01.034","article-title":"Apoptotic cell-mimicking gold nanocages loaded with LXR agonist for attenuating the progression of murine systemic lupus erythematosus","volume":"197","author":"Xu","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2026.119706_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.matdes.2024.112951","article-title":"Carrier-free poly(glycyrrhetinic acid)-facilitated celastrol-loaded nanoparticle for high-efficiency low-toxicity treatment of rheumatoid arthritis","volume":"241","author":"Zhang","year":"2024","journal-title":"Mater. & Des."},{"key":"10.1016\/j.biopha.2026.119706_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113898","article-title":"Evolution of nanomedicines for the treatment of autoimmune disease: From vehicles for drug delivery to inducers of bystander immunoregulation","volume":"176","author":"Yang","year":"2021","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2026.119706_bib62","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1023\/A:1015123024113","article-title":"Prolonged Anti-Inflammatory Action of DL-Lactide\/Glycolide Copolymer Nanospheres Containing Betamethasone Sodium Phosphate for an Intra-Articular Delivery System in Antigen-Induced Arthritic Rabbit","volume":"19","author":"Horisawa","year":"2002","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib63","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1021\/acsami.1c21595","article-title":"Multistage-Responsive Nanocomplexes Attenuate Ulcerative Colitis by Improving the Accumulation and Distribution of Oral Nucleic Acid Drugs in the Colon","volume":"14","author":"Li","year":"2022","journal-title":"ACS Appl. Mater. & Interfaces"},{"issue":"23","key":"10.1016\/j.biopha.2026.119706_bib64","doi-asserted-by":"crossref","first-page":"24404","DOI":"10.1021\/acsnano.3c11089","article-title":"Orally Administrated Inflamed Colon-Targeted Nanotherapeutics for Inflammatory Bowel Disease Treatment by Oxidative Stress Level Modulation in Colitis","volume":"17","author":"Min","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.biopha.2026.119706_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2023.121018","article-title":"Hyaluronic acid-based M1 macrophage targeting and environmental responsive drug releasing nanoparticle for enhanced treatment of rheumatoid arthritis","volume":"316","author":"Wang","year":"2023","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.biopha.2026.119706_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.132586","article-title":"Bridging the gap in rheumatoid arthritis treatment with hyaluronic acid-based drug delivery approaches","volume":"271","author":"Priya","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.biopha.2026.119706_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.111845","article-title":"PAMAM dendrimers functionalised with an anti-TNF \u03b1 antibody and chondroitin sulphate for treatment of rheumatoid arthritis","volume":"121","author":"Oliveira","year":"2021","journal-title":"Materials Science Engineering C"},{"issue":"4","key":"10.1016\/j.biopha.2026.119706_bib68","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1021\/acsnano.4c15164","article-title":"Extracellular Matrix-Inspired Dendrimer Nanogels Encapsulating Cyclophosphamide for Systemic Sclerosis Treatment","volume":"19","author":"Lu","year":"2025","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib69","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/s41467-023-36625-7","article-title":"Fluorinated polyamidoamine dendrimer-mediated miR-23b delivery for the treatment of experimental rheumatoid arthritis in rats","volume":"14","author":"Han","year":"2023","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.biopha.2026.119706_bib70","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid Nanoparticles\u2500From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"issue":"7","key":"10.1016\/j.biopha.2026.119706_bib71","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/14737140.2016.1192471","article-title":"The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy","volume":"16","author":"Passero","year":"2016","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2026.119706_bib72","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/pharmaceutics9020012","article-title":"Liposomal Formulations in Clinical Use: An Updated Review","volume":"9","author":"Bulbake","year":"2017","journal-title":"Pharmaceutics"},{"issue":"47","key":"10.1016\/j.biopha.2026.119706_bib73","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo5284","article-title":"Tolerogenic nanoparticles induce type II collagen\u2013specific regulatory T cells and ameliorate osteoarthritis","volume":"8","author":"Sohn","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2026.119706_bib74","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jconrel.2018.08.007","article-title":"Peptide-directed liposomal delivery improves the therapeutic index of an immunomodulatory cytokine in controlling autoimmune arthritis","volume":"286","author":"Meka","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119706_bib75","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jconrel.2021.05.027","article-title":"New strategy for MS treatment with autoantigen-modified liposomes and their therapeutic effect","volume":"335","author":"Shimizu","year":"2021","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib76","article-title":"Nano-enabled immunomodulation","volume":"16","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biopha.2026.119706_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105139","article-title":"Nanomaterials for direct and indirect immunomodulation: A review of applications","volume":"142","author":"Kubackova","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119706_bib78","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cytogfr.2024.10.001","article-title":"The Yin and Yang of TLR4 in COVID-19","volume":"82","author":"Mukherjee","year":"2025","journal-title":"Cytokine Growth Factor. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2026.119706_bib79","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbadis.2010.07.008","article-title":"The role of antigen presenting cells in multiple sclerosis","volume":"1812","author":"Chastain","year":"2011","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Mol. Basis Dis."},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib80","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41392-025-02326-4","article-title":"Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential","volume":"10","author":"Wang","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib81","article-title":"Immunomodulation of Nanoparticles in Nanomedicine Applications","volume":"2014","author":"Jiao","year":"2014","journal-title":"BioMed. Res. Int."},{"issue":"7","key":"10.1016\/j.biopha.2026.119706_bib82","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nnano.2009.151","article-title":"Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in mice","volume":"4","author":"Mitchell","year":"2009","journal-title":"Nat. Nanotechnol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119706_bib83","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/cns.12121","article-title":"The Suppressive Effect of IL-27 on Encephalitogenic Th17 Cells Induced by Multiwalled Carbon Nanotubes Reduces the Severity of Experimental Autoimmune Encephalomyelitis","volume":"19","author":"Moraes","year":"2013","journal-title":"CNS Neurosci. & Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib84","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12951-016-0159-z","article-title":"Anti-inflammatory effect of fullerene C60 in a mice model of atopic dermatitis","volume":"14","author":"Shershakova","year":"2016","journal-title":"J. Nanobiotechnology"},{"issue":"4","key":"10.1016\/j.biopha.2026.119706_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126290","article-title":"Inhibition of Inflammatory Arthritis Using Fullerene Nanomaterials","volume":"10","author":"Dellinger","year":"2015","journal-title":"PLOS ONE"},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib86","article-title":"Autoimmune hepatitis","volume":"4","author":"Mieli-Vergani","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"5","key":"10.1016\/j.biopha.2026.119706_bib87","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1021\/acsami.3c16168","article-title":"Curdlan-Decorated Fullerenes Mitigate Immune-Mediated Hepatic Injury for Autoimmune Hepatitis Therapeutics via Reducing Macrophage Infiltration","volume":"16","author":"Fei","year":"2024","journal-title":"ACS Appl. Mater. & Interfaces"},{"key":"10.1016\/j.biopha.2026.119706_bib88","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.msec.2018.08.033","article-title":"Effect of \u042160 fullerenes on the intensity of colon damage and hematological signs of ulcerative colitis in rats","volume":"93","author":"Byelinska","year":"2018","journal-title":"Materials Science Engineering C"},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib89","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-46671-1","article-title":"Therapeutic effect of gold nanoparticles on DSS-induced ulcerative colitis in mice with reference to interleukin-17 expression","volume":"9","author":"Abdelmegid","year":"2019","journal-title":"Sci. Rep."},{"issue":"16","key":"10.1016\/j.biopha.2026.119706_bib90","doi-asserted-by":"crossref","first-page":"7648","DOI":"10.1039\/D0NR09153G","article-title":"Gold nanoparticles (AuNPs) impair LPS-driven immune responses by promoting a tolerogenic-like dendritic cell phenotype with altered endosomal structures","volume":"13","author":"Michelini","year":"2021","journal-title":"Nanoscale"},{"key":"10.1016\/j.biopha.2026.119706_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2026.124329","article-title":"Bifunctional Ferritin Nanoparticle Blocks PD-1\/PD-L1 Pathway and Alleviates Oxidative Stress for Multi-Target Therapy of Multiple Sclerosis","author":"Yang","year":"2026","journal-title":"Biomaterials"},{"issue":"43","key":"10.1016\/j.biopha.2026.119706_bib92","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj1019","article-title":"Inhibition of neutrophil extracellular trap formation alleviates vascular dysfunction in type 1 diabetic mice","volume":"9","author":"Liu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2026.119706_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.571489","article-title":"Neutrophil Inflammatory Response Is Downregulated by Uptake of Superparamagnetic Iron Oxide Nanoparticle Therapeutics","volume":"11","author":"Garcia","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119706_bib94","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3109\/17435390.2010.541293","article-title":"Biomedical nanoparticles modulate specific CD4+ T cell stimulation by inhibition of antigen processing in dendritic cells","volume":"5","author":"Blank","year":"2011","journal-title":"Nanotoxicology"},{"issue":"26","key":"10.1016\/j.biopha.2026.119706_bib95","doi-asserted-by":"crossref","first-page":"33106","DOI":"10.1021\/acsami.4c05428","article-title":"Administration of ROS-Scavenging Cerium Oxide Nanoparticles Simply Mixed with Autoantigenic Peptides Induce Antigen-Specific Immune Tolerance against Autoimmune Encephalomyelitis","volume":"16","author":"Nguyen","year":"2024","journal-title":"ACS Appl. Mater. & Interfaces"},{"key":"10.1016\/j.biopha.2026.119706_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2025.1580062","article-title":"Cerium oxide nanoparticles attenuates fibrosis and inflammation in thyroid-associated ophthalmopathy via JNK pathway","volume":"12","author":"Wang","year":"2025","journal-title":"Front. Mol. Biosci."},{"issue":"7","key":"10.1016\/j.biopha.2026.119706_bib97","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S2213-8587(25)00066-X","article-title":"Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management","volume":"13","author":"Wiersinga","year":"2025","journal-title":"Lancet Diabetes & Endocrinol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119706_bib98","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/pharmaceutics13111841","article-title":"Immunomodulatory Nanoparticles Mitigate Macrophage Inflammation via Inhibition of PAMP Interactions and Lactate-Mediated Functional Reprogramming of NF-\u03baB and p38 MAPK","volume":"13","author":"Lasola","year":"2021","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.biopha.2026.119706_bib99","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1073\/pnas.1408686111","article-title":"Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance","volume":"112","author":"Maldonado","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2026.119706_bib100","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1080\/21645515.2021.1872342","article-title":"Polymeric nanoparticles containing rapamycin and autoantigen induce antigen-specific immunological tolerance for preventing vitiligo in mice","volume":"17","author":"Zhang","year":"2021","journal-title":"Human. Vaccin. & Immunother."},{"issue":"10","key":"10.1016\/j.biopha.2026.119706_bib101","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1021\/acschembio.1c00212","article-title":"Tolerogenic Nanoparticles Impacting B and T Lymphocyte Responses Delay Autoimmune Arthritis in K\/BxN Mice","volume":"16","author":"Srivastava","year":"2021","journal-title":"ACS Chem. Biol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119706_bib102","doi-asserted-by":"crossref","first-page":"20206","DOI":"10.1021\/acsnano.2c05643","article-title":"Suppression of Autoimmune Rheumatoid Arthritis with Hybrid Nanoparticles That Induce B and T Cell Tolerance to Self-Antigen","volume":"16","author":"Brzezicka","year":"2022","journal-title":"ACS Nano"},{"issue":"50","key":"10.1016\/j.biopha.2026.119706_bib103","doi-asserted-by":"crossref","first-page":"32017","DOI":"10.1073\/pnas.2016451117","article-title":"Tolerogenic nanoparticles suppress central nervous system inflammation","volume":"117","author":"Kenison","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"31","key":"10.1016\/j.biopha.2026.119706_bib104","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202401423","article-title":"Macrophage-Mimicking Cellular Nanoparticles Scavenge Proinflammatory Cytokines in Specimens of Patients with Inflammatory Disorders","volume":"11","author":"Zhou","year":"2024","journal-title":"Adv. Sci."},{"issue":"37","key":"10.1016\/j.biopha.2026.119706_bib105","doi-asserted-by":"crossref","first-page":"13481","DOI":"10.1073\/pnas.1412420111","article-title":"Clearance of pathological antibodies using biomimetic nanoparticles","volume":"111","author":"Copp","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"32","key":"10.1016\/j.biopha.2026.119706_bib106","doi-asserted-by":"crossref","first-page":"11619","DOI":"10.1039\/D2NR02601E","article-title":"A neutrophil cell membrane-biomimetic nanoplatform based on l-arginine nanoparticles for early osteoarthritis diagnosis and nitric oxide therapy","volume":"14","author":"Yu","year":"2022","journal-title":"Nanoscale"},{"issue":"12","key":"10.1016\/j.biopha.2026.119706_bib107","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/s41565-018-0254-4","article-title":"Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis","volume":"13","author":"Zhang","year":"2018","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biopha.2026.119706_bib108","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.biomaterials.2016.10.003","article-title":"Nanoparticles camouflaged in platelet membrane coating as an antibody decoy for the treatment of immune thrombocytopenia","volume":"111","author":"Wei","year":"2016","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.biopha.2026.119706_bib109","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.4049\/jimmunol.1701171","article-title":"rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and Fc\u03b3Rs","volume":"200","author":"Spirig","year":"2018","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119706_bib110","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3390\/ijms27031277","article-title":"Recombinant Human IgG1-Hexamer Reduces Pathogenic Autoantibodies in the K\/BxN Mouse Model of Arthritis Independent of FcRn","volume":"27","author":"Lewis","year":"2026","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2026.119706_bib111","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41584-018-0013-9","article-title":"Multimerized IgG1 Fc molecule as an anti-inflammatory agent","volume":"14","author":"Stephen-Victor","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib112","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s42003-018-0149-9","article-title":"Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions","volume":"1","author":"Rowley","year":"2018","journal-title":"Commun. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib113","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12951-023-02269-4","article-title":"Correction: Evidence of brain target engagement in Parkinson\u2019s disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials","volume":"22","author":"Ren","year":"2024","journal-title":"J. Nanobiotechnology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib114","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/s12951-023-02236-z","article-title":"Evidence of brain target engagement in Parkinson\u2019s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials","volume":"21","author":"Ren","year":"2023","journal-title":"J. Nanobiotechnology"},{"issue":"3","key":"10.1016\/j.biopha.2026.119706_bib115","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/jfmk7030052","article-title":"A Clinical Study to Evaluate the Safety and Efficacy of Oral Administration of Microscopic Dose Gold Nanoparticle (AuNP) on Knee Joint Health and Function in Arthritis Patients","volume":"7","author":"Han","year":"2022","journal-title":"J. Funct. Morphol. Kinesiol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib116","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltac002","article-title":"Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes","volume":"2","author":"Tatovic","year":"2022","journal-title":"Immunother. Adv."},{"key":"10.1016\/j.biopha.2026.119706_bib117","unstructured":"In Vivo Characterization of Inflammation With Ferumoxytol, on 7 Tesla Magnetic Resonance Imaging, ClinicalTrails.gov Identifier: NCT02511028; National Institute of Health Clinical Center: (2015) Bethesda, MD, USA, 2015."},{"issue":"11","key":"10.1016\/j.biopha.2026.119706_bib118","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc19-0152","article-title":"Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 Diabetes","volume":"42","author":"Klonoff","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.biopha.2026.119706_bib119","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s00784-025-06159-x","article-title":"Rebamipide for management of methotrexate-induced oral ulcers: a three-arm randomized clinical trial","volume":"29","author":"Abdelaziz","year":"2025","journal-title":"Clin. Oral. Investig."},{"key":"10.1016\/j.biopha.2026.119706_bib120","unstructured":"Gold Factor on Knee Joint Health and Function). ClinicalTrials.gov ID NCT05347602. Professional Athletic Orthopedics, St. Louis University. 2020."},{"key":"10.1016\/j.biopha.2026.119706_bib121","unstructured":"Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients. ClinicalTrials.gov ID\u00a0NCT04649697. Randomized-Controlled Clinical Trial, 2020."},{"issue":"3","key":"10.1016\/j.biopha.2026.119706_bib122","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1042\/BST0350527","article-title":"Health effects of nanomaterials","volume":"35","author":"Tetley","year":"2007","journal-title":"Biochem. Soc. Trans."},{"issue":"5","key":"10.1016\/j.biopha.2026.119706_bib123","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/jat.4420","article-title":"Influences of repeated exposure to low levels of TiO2 nanoparticles on Kruppel-like factors in 3D Caco-2 spheroids and mouse intestines","volume":"43","author":"Cao","year":"2023","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.biopha.2026.119706_bib124","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.2147\/IJN.S170723","article-title":"Potential adverse effects of nanoparticles on the reproductive system","volume":"13","author":"Wang","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119706_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpc.2024.109838","article-title":"Assessing cardiovascular toxicity in zebrafish embryos exposed to copper nanoparticles","volume":"277","author":"Hsiao","year":"2024","journal-title":"Comparative Biochemistry Physiology Part C Toxicology & Pharmacology"},{"issue":"4","key":"10.1016\/j.biopha.2026.119706_bib126","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/10934529.2012.650576","article-title":"Zinc oxide nanoparticles cause nephrotoxicity and kidney metabolism alterations in rats","volume":"47","author":"Yan","year":"2012","journal-title":"J. Environ. Sci. Health Part. A"},{"issue":"4","key":"10.1016\/j.biopha.2026.119706_bib127","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/10934529.2012.650576","article-title":"Zinc oxide nanoparticles cause nephrotoxicity and kidney metabolism alterations in rats","volume":"47","author":"Yan","year":"2012","journal-title":"J. Environ. Sci. Health Part. A"},{"key":"10.1016\/j.biopha.2026.119706_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecoenv.2026.120165","article-title":"Size-dependent neurotoxicity of PbSe nanoparticles: Oxidative stress, apoptosis, and synaptic dysfunction mediate cognitive impairment in rats","volume":"316","author":"Yue","year":"2026","journal-title":"Ecotoxicol. Environ. Saf."},{"issue":"3","key":"10.1016\/j.biopha.2026.119706_bib129","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11051-023-05690-w","article-title":"Structural parameters of nanoparticles affecting their toxicity for biomedical applications: a review","volume":"25","author":"Abbasi","year":"2023","journal-title":"J. Nanopart. Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119706_bib130","doi-asserted-by":"crossref","DOI":"10.1088\/1748-605X\/abe5fa","article-title":"Biocompatibility of nanomaterials and their immunological properties","volume":"16","author":"Kyriakides","year":"2021","journal-title":"Biomed. Mater."},{"key":"10.1016\/j.biopha.2026.119706_bib131","doi-asserted-by":"crossref","unstructured":"2025, The benefits and risks of PEGylation in nanomedicine, Nature Nanotechnology 20(5) (2025) 575-575.","DOI":"10.1038\/s41565-025-01951-y"},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib132","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1038\/s41598-017-04229-z","article-title":"The Effect of shape on Cellular Uptake of Gold Nanoparticles in the forms of Stars, Rods, and Triangles","volume":"7","author":"Xie","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119706_bib133","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/jfb16010024","article-title":"Biodegradable and Stimuli-Responsive Nanomaterials for Targeted Drug Delivery in Autoimmune Diseases","volume":"16","author":"Parvin","year":"2025","journal-title":"J. Funct. Biomater."},{"key":"10.1016\/j.biopha.2026.119706_bib134","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.actbio.2020.11.047","article-title":"Alternating stealth polymer coatings between administrations minimizes toxic and antibody immune responses towards nanomedicine treatment regimens","volume":"121","author":"Li","year":"2021","journal-title":"Acta Biomater."},{"issue":"28","key":"10.1016\/j.biopha.2026.119706_bib135","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adw1731","article-title":"Enhanced immunocompatibility and hemocompatibility of nanomedicines across multiple species using complement pathway inhibitors","volume":"11","author":"Li","year":"2025","journal-title":"Sci. Adv."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T23:19:18Z","timestamp":1785971958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226007420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":135,"alternative-id":["S0753332226007420"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119706","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unleashing the prospects of nanomaterials in the treatment of autoimmune and inflammatory diseases","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119706"}}